

Yubin Kang

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/803429/publications.pdf>

Version: 2024-02-01

49
papers

1,268
citations

471371

17
h-index

377752

34
g-index

49
all docs

49
docs citations

49
times ranked

2484
citing authors

#	ARTICLE	IF	CITATIONS
1	Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy. <i>Leukemia</i> , 2019, 33, 2266-2275.	3.3	385
2	A tumor-intrinsic PD-L1/NLRP3 inflammasome signaling pathway drives resistance to anti-PD-1 immunotherapy. <i>Journal of Clinical Investigation</i> , 2020, 130, 2570-2586.	3.9	134
3	Inhibition of sphingosine kinase 2 downregulates the expression of c-Myc and Mcl-1 and induces apoptosis in multiple myeloma. <i>Blood</i> , 2014, 124, 1915-1925.	0.6	89
4	Intravital imaging of mouse embryos. <i>Science</i> , 2020, 368, 181-186.	6.0	70
5	Selective Enhancement of Donor Hematopoietic Cell Engraftment by the CXCR4 Antagonist AMD3100 in a Mouse Transplantation Model. <i>PLoS ONE</i> , 2010, 5, e11316.	1.1	40
6	Prediction of Poor Mobilization of Autologous CD34+ Cells with Growth Factor in Multiple Myeloma Patients: Implications for Risk-Stratification. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 222-228.	2.0	36
7	Inhibition of thioredoxin activates mitophagy and overcomes adaptive bortezomib resistance in multiple myeloma. <i>Journal of Hematology and Oncology</i> , 2018, 11, 29.	6.9	36
8	Abnormal hematopoietic phenotypes in Pim kinase triple knockout mice. <i>Journal of Hematology and Oncology</i> , 2013, 6, 12.	6.9	35
9	Plasma cell disorders in HIV-infected patients: epidemiology and molecular mechanisms. <i>Biomarker Research</i> , 2013, 1, 8.	2.8	31
10	Pim1 Serine/Threonine Kinase Regulates the Number and Functions of Murine Hematopoietic Stem Cells. <i>Stem Cells</i> , 2013, 31, 1202-1212.	1.4	30
11	Metabolic alterations and the potential for targeting metabolic pathways in the treatment of multiple myeloma. <i>Journal of Cancer Metastasis and Treatment</i> , 2019, 2019, .	0.5	28
12	Unmanipulated or CD34 selected haplotype mismatched transplants. <i>Current Opinion in Hematology</i> , 2008, 15, 561-567.	1.2	27
13	PINK1-Dependent Mitophagy Regulates the Migration and Homing of Multiple Myeloma Cells via the MOB1-Mediated Hippo-YAP/TAZ Pathway. <i>Advanced Science</i> , 2020, 7, 1900860.	5.6	27
14	Comparison of Cilta-cel, an Anti-BCMA CAR-T Cell Therapy, Versus Conventional Treatment in Patients With Relapsed/Refractory Multiple Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2022, 22, 326-335.	0.2	27
15	Plerixafor (a CXCR4 antagonist) following myeloablative allogeneic hematopoietic stem cell transplantation enhances hematopoietic recovery. <i>Journal of Hematology and Oncology</i> , 2016, 9, 71.	6.9	20
16	The combination of a sphingosine kinase 2 inhibitor (ABC294640) and a Bcl-2 inhibitor (ABT-199) displays synergistic anti-myeloma effects in myeloma cells without a t(11;14) translocation. <i>Cancer Medicine</i> , 2018, 7, 3257-3268.	1.3	20
17	Overall survival of patients with triple-class refractory multiple myeloma treated with selinexor plus dexamethasone vs standard of care in MAMMOTH. <i>American Journal of Hematology</i> , 2021, 96, E5-E8.	2.0	20
18	Insulin-Like Growth Factor 1 Mitigates Hematopoietic Toxicity After Lethal Total Body Irradiation. <i>International Journal of Radiation Oncology Biology Physics</i> , 2013, 85, 1141-1148.	0.4	19

#	ARTICLE	IF	CITATIONS
19	The promise of chimeric antigen receptor (CAR) T cell therapy in multiple myeloma. Cellular Immunology, 2019, 345, 103964.	1.4	18
20	Thioredoxin and Hematologic Malignancies. Advances in Cancer Research, 2014, 122, 245-279.	1.9	16
21	Thioredoxin mitigates radiation-induced hematopoietic stem cell injury in mice. Stem Cell Research and Therapy, 2017, 8, 263.	2.4	16
22	Calcium/Calmodulin Dependent Protein Kinase Kinase 2 Regulates the Expansion of Tumor-Induced Myeloid-Derived Suppressor Cells. Frontiers in Immunology, 2021, 12, 754083.	2.2	16
23	Pim1 kinase regulates c-Kit gene translation. Experimental Hematology and Oncology, 2016, 5, 31.	2.0	15
24	The challenges of checkpoint inhibition in the treatment of multiple myeloma. Cellular Immunology, 2018, 334, 87-98.	1.4	15
25	Pan-PIM kinase inhibitors enhance Lenalidomide's anti-myeloma activity via cereblon-IKZF1/3 cascade. Cancer Letters, 2019, 440-441, 1-10.	3.2	15
26	Phase I dose escalation study of naive T-cell depleted donor lymphocyte infusion following allogeneic stem cell transplantation. Bone Marrow Transplantation, 2021, 56, 137-143.	1.3	15
27	PIM Kinases in Multiple Myeloma. Cancers, 2021, 13, 4304.	1.7	15
28	Chimeric antigen receptor (CAR) T-cell therapy for multiple myeloma. , 2022, 232, 108007.		12
29	Subsequent Treatment Outcomes of Multiple Myeloma Refractory to CD38-Monoclonal Antibody Therapy. Blood, 2018, 132, 2015-2015.	0.6	10
30	The impact of bone marrow fibrosis and JAK2 expression on clinical outcomes in patients with newly diagnosed multiple myeloma treated with immunomodulatory agents and/or proteasome inhibitors. Cancer Medicine, 2020, 9, 5869-5880.	1.3	8
31	Proteomic analysis of murine bone marrow niche microenvironment identifies thioredoxin as a novel agent for radioprotection and for enhancing donor cell reconstitution. Experimental Hematology, 2013, 41, 944-956.	0.2	6
32	Senile transthyretin cardiac amyloidosis in patients with plasma cell dyscrasias: importance of cardiac biopsy for making the correct diagnosis. , 2014, 1, .		4
33	Emerging Evidence of the Significance of Thioredoxin-1 in Hematopoietic Stem Cell Aging. Antioxidants, 2022, 11, 1291.	2.2	3
34	Gamma Gap: A Point-of-Care Test That Correlates With Disease Burden and Treatment Response in Multiple Myeloma. JCO Oncology Practice, 2020, 16, e751-e757.	1.4	2
35	Plerixafor (Mozobil®) Selectively Enhances Donor Hematopoietic Cell Engraftment.. Blood, 2009, 114, 368-368.	0.6	2
36	Anaplastic Multiple Myeloma: Case Series and Literature Review. , 2022, 5, 1-11.		2

#	ARTICLE	IF	CITATIONS
37	Comparison Between Pegfilgrastim and Filgrastim-Based Autologous Hematopoietic Stem Cell Mobilization in the Setting of Patient Adapted (â€œJust in Timeâ€) Plerixafor: Efficacy and Cost Analysis. Blood, 2011, 118, 1921-1921.	0.6	1
38	Sphingolipids As a Novel Target For The Treatment Of Multiple Myeloma. Blood, 2013, 122, 3163-3163.	0.6	1
39	Phase 1 Trial Of Carfilzomib + High Dose Melphalan Conditioning Regimen Prior To Autologous Hematopoietic Stem Cell Transplantation (AHSCT) For Relapsed Multiple Myeloma. Blood, 2013, 122, 3329-3329.	0.6	1
40	Phase I/II dose expansion of a trial investigating bendamustine and pomalidomide with dexamethasone (BPd) in patients with relapsed/refractory multiple myeloma.. Journal of Clinical Oncology, 2017, 35, 8008-8008.	0.8	1
41	A Prospective Study of Donor ImmuKnowÂ® as a Biomarker for Acute GvHD in Hematopoietic Cell Transplantation Recipients.. Blood, 2009, 114, 4646-4646.	0.6	0
42	Potential Use of Sphingosine Kinase-2 Selective Inhibitors for the Treatment of Multiple Myeloma. Blood, 2011, 118, 5105-5105.	0.6	0
43	Characterization of Pim Protein Kinases and Evaluation of Small Molecule Inhibitors in Multiple Myeloma. Blood, 2011, 118, 2909-2909.	0.6	0
44	A Novel Role of Pim Serine/Threonine Kinases in Hematopoiesis: Pim 1 Kinase Increases Hematopoietic Stem Cell Population. Blood, 2011, 118, 561-561.	0.6	0
45	Regulation and Functional Role of Beta2-Adrenergic Receptor in Acute Myelogenous Leukemia. Blood, 2011, 118, 2563-2563.	0.6	0
46	Pim1 Serine/Threonine Kinase Regulates the Number and Functions of Murine Hematopoietic Stem Cells.. Blood, 2012, 120, 2303-2303.	0.6	0
47	Sphingolipids as a novel target for the treatment of multiple myeloma.. Journal of Clinical Oncology, 2013, 31, e19534-e19534.	0.8	0
48	Similar Dynamics Of Intra Apheresis Autologous CD34+ Recruitment and Collection Efficiency In Patients Undergoing Mobilization With Or Without Plerixafor. Blood, 2013, 122, 904-904.	0.6	0
49	Induction Therapy with Bortezomib and Dexamethasone Followed By Autologous Stem Cell Transplantation for Systemic Light Chain Amyloidosis: Our Experience. Blood, 2014, 124, 5907-5907.	0.6	0